Skip to main content
Clinical Trials/NCT00787800
NCT00787800
Completed
Phase 4

Reduction And Prevention of Tachyarrhythmias and Shocks Using Reduced Ventricular Pacing With Atrial Algorithms (The RAPTURE Study)

Mayo Clinic3 sites in 2 countries100 target enrollmentNovember 2008

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Ventricular Tachycardia
Sponsor
Mayo Clinic
Enrollment
100
Locations
3
Primary Endpoint
Number of Subjects Inappropriately Shocked by Implantable Cardioverter-Defibrillator (ICD)
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

The RAPTURE Study will determine whether dual chamber defibrillators with atrial prevention and termination therapies, minimized ventricular pacing, and remote monitoring will reduce the rate of inappropriate shocks and improve quality of life compared to optimally programmed back-up pacing only single chamber ICDs when used for primary prevention of sudden cardiac death

Detailed Description

While implantable cardioverter-defibrillator (ICD) therapy has become the gold standard for sudden death prevention in high risk individuals, reduction of device associated morbidity remains a significant problem. Rapidly conducted atrial tachyarrhythmias inappropriately detected as ventricular tachycardia (VT) are the most common cause for inappropriate shocks in ICD recipients, affecting 10 to 40% of patients. Large multicenter trials have shown modest benefits of atrial pacing in preventing atrial fibrillation, however right ventricular (RV) pacing was not limited, thus any favorable effects associated with atrial prevention and treatment may have been offset by the RV pacing. New algorithms to prevent RV pacing are now made available in our current devices. The choice of dual chamber versus single chamber ICD for primary prevention warrants re-assessment of atrial prevention and termination therapies, without the potentially adverse effects of RV pacing. This Multi Center Pilot study will enroll 100 eligible subjects, 50 to single chamber and 50 to dual chamber ICDs. Patients will be followed for one year.

Registry
clinicaltrials.gov
Start Date
November 2008
End Date
December 2011
Last Updated
11 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Paul A. Friedman

MD

Mayo Clinic

Eligibility Criteria

Inclusion Criteria

  • Candidates for ICD for primary prevention according to American Heart Association/American College of Cardiology (AHA/ACC) guidelines who have a clinical indication for ICD implantation for ventricular arrhythmia or sudden death prevention.
  • The ability to understand the scope of the study, provide written informed consent, and a willingness to complete all study visits and associated procedures.

Exclusion Criteria

  • Pregnant women
  • Age \<18 years old
  • Inability to provide consent
  • On a heart transplant waiting list
  • Life expectancy \<1 year
  • Indication for pacing
  • Atrioventricular (AV) node ablation
  • Permanent atrial fibrillation or atrial flutter
  • Indication for cardiac resynchronization
  • Preexisting, separate pacemaker pulse generator that won't be explanted

Outcomes

Primary Outcomes

Number of Subjects Inappropriately Shocked by Implantable Cardioverter-Defibrillator (ICD)

Time Frame: Baseline to 12 months after ICD implantation

An inappropriate shock is defined as a shock delivered by the ICD during a rhythm other than sustained VT/VF (ventricular tachycardia/ventricular fibrillation).

Secondary Outcomes

  • Number of Atrial Tachyarrhythmia Episodes Lasting Over 5 Minutes(Baseline to 12 Months)
  • Number of Appropriate Shocks by ICD(Baseline to 12 Months)
  • Total Cost of ICD Implantation Procedure(Baseline)
  • Number of Subjects With Newly Detected Atrial Tachyarrhythmias(Baseline to 12 months after ICD implantation)
  • Atrial Fibrillation (AF) Burden(Implantation through 1 year)

Study Sites (3)

Loading locations...

Similar Trials